Evidence-based·Last reviewed May 31, 2026·How we grade evidence

SAMe

VitaminMethyl donorBest taken away from food

SAMe is a naturally occurring methyl donor sold as a supplement in the US and as a prescription drug in parts of Europe. The strongest case is for mild-to-moderate depression and knee osteoarthritis, where multiple RCTs and meta-analyses show effects comparable to standard antidepressants and NSAIDs respectively, with fewer side effects. Onset is slower than for prescription drugs.

Quick decision guide

May help most

Adults with mild-to-moderate depression looking for an alternative or adjunct to SSRIs; adults with knee or hip osteoarthritis pain who tolerate NSAIDs poorly. Always run by your clinician — drug interactions are real.

Common dosing range

400–1,600 mg/day, divided into 1–2 doses, on an empty stomach. Most depression trials used 800–1,600 mg/day; OA trials used 600–1,200 mg/day.

When to expect effects

Depression: 2–6 weeks. OA: 4–8 weeks (slower onset than NSAIDs but eventually equivalent in trials).

Watch out for

Can trigger mania in undiagnosed bipolar disorder. Don't combine with SSRIs, MAOIs, or other serotonergic drugs without clinician supervision (serotonin syndrome risk). Pregnancy safety not established.

Evidence snapshot

Depression (monotherapy, mild–moderate)Moderate

Knee/hip osteoarthritis painModerate

Cholestatic liver diseaseModerate

FibromyalgiaLow–Emerging

Cognitive support / brain fogLow

What is it

SAMe (S-adenosyl-L-methionine) is a naturally occurring compound present in every cell of the body. It is the body's principal methyl donor, participating in over 100 methyl-transfer reactions essential for neurotransmitter synthesis, DNA regulation, joint health, and liver function.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have mild-to-moderate depression and want a supplement option alongside or instead of an SSRI (with clinician guidance)

You have knee or hip osteoarthritis and NSAIDs cause stomach issues or are contraindicated

Your clinician has flagged early cholestatic liver disease and is considering adjunct SAMe

You've ruled out bipolar disorder and aren't on serotonergic medications

You can absorb the cost — SAMe is expensive (often $50–100+/month for therapeutic doses)

Probably skip if…

You have a personal or family history of bipolar disorder — mania risk

You're on SSRIs, MAOIs, SNRIs, tramadol, or St. John's wort — serotonin syndrome risk

You're on levodopa (without carbidopa) for Parkinson's — SAMe can methylate levodopa and reduce effect

You expect immediate pain or mood relief — SAMe takes weeks to work

You're pregnant or breastfeeding — safety not established

Cost is a barrier — generic SSRIs and NSAIDs are far cheaper and faster acting

Evidence at a glance

Goal	Effect	Best fit	Time
Major depressive disorder (mild–moderate) Good Evidence	Moderate effect vs placebo (SMD ~0.58); equivalent to standard antidepressants in head-to-head trials	Adults with mild-to-moderate depression who can't tolerate SSRIs or prefer a supplement option, with clinician oversight	2–6 weeks
Osteoarthritis (knee, hip) pain Good Evidence	Pain reduction equivalent to celecoxib/NSAIDs by 4–8 weeks; slower onset than NSAIDs	Adults with knee or hip OA who can't tolerate NSAIDs (GI issues, kidney concerns) or want to reduce NSAID use	4–8 weeks for full effect
Cholestatic liver disease / intrahepatic cholestasis of pregnancy Good Evidence	Reduction in liver enzymes and bile acids in cholestasis trials; subjective itching improvement	Adults with diagnosed cholestatic liver disease under hepatology care	Weeks for biomarker change
Fibromyalgia Limited Evidence	Modest pain and mood improvement in small trials	Adults with fibromyalgia who haven't tried SAMe and want to test it under clinician guidance	4–6 weeks
Cognitive support / 'brain fog' Mixed Evidence	No clinical-endpoint benefit demonstrated in healthy adults	Adults with diagnosed mood disorder where cognitive symptoms are part of depression — improving depression often improves cognition	Not established

Major depressive disorder (mild–moderate)

Good Evidence

Effect: Moderate effect vs placebo (SMD ~0.58); equivalent to standard antidepressants in head-to-head trials
Best fit: Adults with mild-to-moderate depression who can't tolerate SSRIs or prefer a supplement option, with clinician oversight
Time: 2–6 weeks

Osteoarthritis (knee, hip) pain

Good Evidence

Effect: Pain reduction equivalent to celecoxib/NSAIDs by 4–8 weeks; slower onset than NSAIDs
Best fit: Adults with knee or hip OA who can't tolerate NSAIDs (GI issues, kidney concerns) or want to reduce NSAID use
Time: 4–8 weeks for full effect

Cholestatic liver disease / intrahepatic cholestasis of pregnancy

Good Evidence

Effect: Reduction in liver enzymes and bile acids in cholestasis trials; subjective itching improvement
Best fit: Adults with diagnosed cholestatic liver disease under hepatology care
Time: Weeks for biomarker change

Fibromyalgia

Limited Evidence

Effect: Modest pain and mood improvement in small trials
Best fit: Adults with fibromyalgia who haven't tried SAMe and want to test it under clinician guidance
Time: 4–6 weeks

Cognitive support / 'brain fog'

Mixed Evidence

Effect: No clinical-endpoint benefit demonstrated in healthy adults
Best fit: Adults with diagnosed mood disorder where cognitive symptoms are part of depression — improving depression often improves cognition
Time: Not established

Evidence for 5 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

Major depressive disorder (mild–moderate)

Supplement benefit

Good Evidence

A 2024 meta-analysis of 23 RCTs (n=2,183) found SAMe monotherapy moderately superior to placebo (SMD -0.58, 95% CI -0.93 to -0.23) and non-inferior to standard antidepressants (SMD 0.06). The earlier AHRQ review (2002) also concluded SAMe was more effective than placebo and equivalent to tricyclic antidepressants with fewer side effects. Augmentation of SSRIs has mixed results.

Effect size

Moderate effect vs placebo (SMD ~0.58); equivalent to standard antidepressants in head-to-head trials

Time to effect

2–6 weeks

Best fit

Adults with mild-to-moderate depression who can't tolerate SSRIs or prefer a supplement option, with clinician oversight

Less likely

Severe depression, bipolar disorder (mania risk), or treatment-resistant depression — needs psychiatric management

Bottom line: Genuine and well-replicated effect in mild-to-moderate depression. Use only with a clinician who knows your medication list and can rule out bipolar.

Evidence is mixed

NCCIH's 2024 summary calls the oral SAMe evidence for depression 'not conclusive', noting many trials were short, small, or used injected formulations. Bioavailability of oral SAMe is variable, and product quality varies between brands.

SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health· conflicting

SourceLimveeraprajak et al., 2024 — Progress in Neuropsychopharmacology & Biological Psychiatry Hardy et al., 2002 (AHRQ) — AHRQ Evidence Report/Technology Assessment No. 64

Osteoarthritis (knee, hip) pain

Supplement benefit

Good Evidence

A 2004 double-blind crossover RCT (n=61) compared SAMe 1,200 mg/day with celecoxib 200 mg/day for 16 weeks in knee OA. Celecoxib worked faster in the first month, but the two were statistically equivalent by month 2. The AHRQ review found SAMe equivalent to NSAIDs in OA with fewer GI side effects. A 2009 Cochrane review (Rutjes) called the evidence inconclusive due to study quality.

Effect size

Pain reduction equivalent to celecoxib/NSAIDs by 4–8 weeks; slower onset than NSAIDs

Time to effect

4–8 weeks for full effect

Best fit

Adults with knee or hip OA who can't tolerate NSAIDs (GI issues, kidney concerns) or want to reduce NSAID use

Less likely

Acute joint flare needing rapid pain control — SAMe is too slow

Bottom line: Reasonable NSAID-sparing option for chronic OA pain. Expect 4–8 weeks for full effect; expensive vs cheap NSAIDs.

Evidence is mixed

The 2009 Cochrane review (Rutjes) called SAMe vs placebo evidence inconclusive due to small trials and quality concerns. Head-to-head with NSAIDs is more consistent.

SourceHardy et al., 2002 (AHRQ) — AHRQ Evidence Report/Technology Assessment No. 64· conflicting

SourceNajm et al., 2004 — BMC Musculoskeletal Disorders Hardy et al., 2002 (AHRQ) — AHRQ Evidence Report/Technology Assessment No. 64

Cholestatic liver disease / intrahepatic cholestasis of pregnancy

Biomarker support

Good Evidence

Most data come from Italy and Spain where SAMe is registered as a prescription drug for liver indications. The AHRQ review found evidence supporting use in cholestasis (including pregnancy-related), with biomarker improvements (bilirubin, ALT). Outside cholestasis, evidence for general 'liver support' is weak.

Effect size

Reduction in liver enzymes and bile acids in cholestasis trials; subjective itching improvement

Time to effect

Weeks for biomarker change

Best fit

Adults with diagnosed cholestatic liver disease under hepatology care

Less likely

Healthy adults with normal LFTs taking SAMe for 'liver health' — no clear benefit

Bottom line: Clinician-directed use in cholestasis only. Not a generic 'liver detox' supplement.

SourceHardy et al., 2002 (AHRQ) — AHRQ Evidence Report/Technology Assessment No. 64

Fibromyalgia

Supplement benefit

Limited Evidence

A small number of older RCTs reported pain, fatigue, and mood improvement with SAMe 800 mg/day vs placebo in fibromyalgia. Trials were small, short, and not replicated at scale. Mechanism (methylation support, mood lift) is plausible.

Effect size

Modest pain and mood improvement in small trials

Time to effect

4–6 weeks

Best fit

Adults with fibromyalgia who haven't tried SAMe and want to test it under clinician guidance

Less likely

Adults who've already tried multiple non-pharmacological adjuncts without benefit

Bottom line: Suggestive but not well replicated. Reasonable trial if other adjuncts haven't worked and your clinician agrees.

SourceHardy et al., 2002 (AHRQ) — AHRQ Evidence Report/Technology Assessment No. 64

Cognitive support / 'brain fog'

Mechanism only

Mixed Evidence

SAMe is essential for neurotransmitter synthesis and brain methylation. Some small studies in mild cognitive impairment and Alzheimer's-adjacent populations suggest possible benefit, but no large RCTs in healthy adults with subjective 'brain fog'. Mechanism is reasonable; clinical evidence in healthy adults is essentially absent.

Effect size

No clinical-endpoint benefit demonstrated in healthy adults

Time to effect

Not established

Best fit

Adults with diagnosed mood disorder where cognitive symptoms are part of depression — improving depression often improves cognition

Less likely

Healthy adults taking SAMe purely for cognitive enhancement

Bottom line: Don't take SAMe specifically for cognition. If depression is the underlying driver, treat that and cognition often improves.

SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health

How it works

SAMe is synthesized inside cells from methionine and ATP by the enzyme methionine adenosyltransferase. Its core function is donating a methyl group (-CH3) to a wide range of acceptors: DNA (controlling gene expression and silencing), neurotransmitters (synthesizing serotonin, dopamine, norepinephrine), phospholipids (membrane structure), creatine, melatonin, hormones, and detoxification intermediates. After donating its methyl group, SAMe becomes S-adenosylhomocysteine and then homocysteine. Homocysteine can return to methionine (via remethylation requiring B12 and folate) or enter transsulfuration to produce cysteine, glutathione, and taurine (requiring B6). The integrity of this cycle requires adequate B-vitamin status. Supplemental SAMe is intended to boost methylation capacity, supporting neurotransmitter synthesis (relevant to mood), cartilage matrix methylation (relevant to osteoarthritis), and liver detoxification (relevant to certain liver diseases).

How to take it

1. Typical dose

• Depression: start 400–800 mg/day; titrate to 800–1,600 mg/day in 1–2 divided doses • Osteoarthritis: 600–1,200 mg/day in 1–2 divided doses • Start low (200–400 mg) for the first week — reduces nausea, headache, and any activation/jitteriness

2. Higher studied dose

Up to 1,600 mg/day in depression trials and 1,200 mg/day in OA trials. Higher doses haven't shown additional benefit and increase cost and side effects.

3. Timing

On an empty stomach (≥30 min before food, or 2 hours after) — improves absorption since SAMe is unstable in stomach acid (hence enteric coating). Take the last dose by mid-afternoon if activating side effects (jitteriness, insomnia) appear.

4. With food

Empty stomach.

5. Split dosing

Split into 2 doses (morning + early afternoon) at total daily doses above 400 mg. Avoid evening dosing if it causes insomnia.

6. How long to try

Try 4–6 weeks at full dose for depression, 8 weeks for OA, before judging effect. Long-term use is reasonable if working; periodic re-assessment with a clinician.

What to track

Depression severity (PHQ-9 every 2–4 weeks)

Joint pain (WOMAC or simple 0–10 scale) for OA

Any signs of mania (elevated mood, decreased sleep, pressured speech, risky behaviour) — stop immediately and call your clinician

Co-supplement B12, folate, and B6 — methylation cycle support and homocysteine prevention

Bottom line: Start low, take on empty stomach, give it weeks not days. Always pair with B-vitamin status check. Stop and call a clinician at the first sign of mania.

3 commercial forms

Compare the main delivery options and what they’re best suited for.

SAMe tosylate disulfate (enteric coated)

Standard US supplement form

The most widely available SAMe salt in US supplements. Stable when enteric-coated, blister-packed, and stored away from heat/moisture. Used in most US trials.

Always verify enteric coating; non-coated tablets are essentially inactive.

SAMe butanedisulfonate (enteric coated)

European/prescription form

Used in European prescription products (e.g., for cholestasis). Slightly different salt; clinical effect is equivalent to tosylate disulfate when dosed for free-SAMe content.

Equivalent at matched free-SAMe doses.

Injectable SAMe

Clinical use only

Some older European trials used IM or IV SAMe (e.g., for liver disease or severe depression). Not available OTC in the US. Not relevant to consumer supplement choices.

Bypasses GI; not a consumer option.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

nauseaGI upsetheadacheinsomnia (especially with late dosing)anxiety / activation (early in treatment)dry mouthdizziness

Serious risks

Mania in undiagnosed or known bipolar disorder. SAMe acts like an antidepressant on mood; in bipolar, this can trigger a manic or hypomanic episode. Screen for bipolar history (family history, prior episodes) before starting.
SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health
Serotonin syndrome when combined with serotonergic medications (SSRIs, SNRIs, MAOIs, tramadol, meperidine, dextromethorphan, St. John's wort, 5-HTP, tryptophan). Symptoms: agitation, sweating, tremor, hyperreflexia, fever. Don't combine without psychiatric oversight.
SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health
Homocysteine elevation — SAMe metabolism generates homocysteine. Co-supplement B12, folate, and B6 to keep homocysteine in range, especially on long-term high-dose SAMe.
SourceHardy et al., 2002 (AHRQ) — AHRQ Evidence Report/Technology Assessment No. 64

Who should avoid it

People with bipolar disorder or significant family history of bipolar — mania risk.
SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health
People taking SSRIs, SNRIs, MAOIs, tramadol, meperidine, dextromethorphan, St. John's wort, 5-HTP, or tryptophan without psychiatric supervision.
SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health
People on levodopa (without carbidopa) for Parkinson's — SAMe can methylate and inactivate levodopa.
SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health
Pregnant or breastfeeding people (safety not established).
SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health
People who are immunocompromised, particularly with HIV — theoretical concern about Pneumocystis risk.
SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health

Pregnancy & breastfeeding

Pregnancy safety has not been formally established for SAMe supplements, though SAMe has been used as a prescription drug in Europe for intrahepatic cholestasis of pregnancy under hospital protocols. For over-the-counter supplement use during pregnancy or breastfeeding: avoid unless a maternal-fetal-medicine specialist has specifically advised it.

SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health

Bottom line: SAMe is reasonably safe for short-to-medium-term use in non-bipolar adults not on serotonergic drugs. Always screen for bipolar; never combine with SSRIs or MAOIs without psychiatric oversight; pair with B-vitamin status.

Interactions

SSRIs, SNRIs (sertraline, fluoxetine, venlafaxine, duloxetine, etc.)Major

Both raise serotonin; combination raises serotonin syndrome risk. Should only be combined under psychiatric supervision, with careful monitoring for agitation, tremor, hyperthermia.

SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health

MAOIs (phenelzine, tranylcypromine, selegiline)Major

Highest risk of serotonin syndrome with SAMe. Avoid combination.

SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health

tramadol, meperidine, dextromethorphan, fentanylMajor

Serotonergic opioids and DXM — combination with SAMe can trigger serotonin syndrome.

SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health

St. John's wort, 5-HTP, L-tryptophanMajor

Other serotonergic supplements — same serotonin syndrome concern. Avoid stacking.

SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health

levodopa (without carbidopa)Moderate

SAMe can methylate and inactivate levodopa, worsening Parkinson's control. The combination tablet (Sinemet) reduces but doesn't eliminate the concern. Discuss with a neurologist.

SourceNCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health

NSAIDsMinor

No pharmacokinetic interaction; sometimes used together for OA. Watch for stacking GI side effects.

Protocols featuring SAMe

Evidence-backed routines where SAMe plays a role.

Mood & Mild Depression

mood

Depression and anxiety are biologically related but mechanistically distinct — Anxiety Relief targets the over-activation pattern; this protocol targets the low-mood, anhedonia, and energy-depletion pattern of mild-to-moderate depression. The supplement category for depression has more rigorous evidence than most realize: SAMe (S-adenosyl methionine) has trial evidence comparable to some SSRIs for mild-to-moderate depression; high-EPA omega-3 has multiple meta-analyses supporting effect; saffron has Iranian and Australian trial evidence comparable to fluoxetine in some studies; vitamin D supplementation reduces depressive symptoms in deficient adults. CRITICAL: This protocol is for MILD-TO-MODERATE depression in adults who are NOT currently in crisis. If you have thoughts of self-harm or suicide, severe symptoms disrupting daily function, or have not improved with conservative measures — please see a mental health professional. SSRIs, SNRIs, and psychotherapy have far larger effect sizes than supplements for moderate-to-severe disease. This is NOT a substitute for proper psychiatric care. If you''re currently taking an antidepressant and want to add supplements, coordinate with your prescriber. Several items below have serotonergic activity that compounds with SSRIs/MAOIs.

Fibromyalgia Support

chronic illness

Fibromyalgia is a real, frequently-dismissed condition affecting an estimated 2-4% of adults — predominantly women between 30 and 60. Its core features are chronic widespread musculoskeletal pain, fatigue, cognitive dysfunction (commonly called "fibro fog"), non-restorative sleep, and frequent comorbidities including IBS, anxiety, and depression. The dominant pathophysiologic model is central sensitization — the central nervous system amplifies pain signals — and a subset of patients also show small-fiber neuropathy on skin biopsy. Mitochondrial dysfunction and oxidative stress are increasingly documented in the fibromyalgia literature. CRITICAL: This protocol is ADJUNCTIVE. Fibromyalgia management is multi-modal, and supplements are one part of a larger plan. Conventional medications (duloxetine, pregabalin, amitriptyline, milnacipran), cognitive behavioral therapy adapted for fibromyalgia (CBT-FM), gentle aerobic exercise as tolerated, and aggressive sleep optimization all have stronger evidence individually than any supplement. That said, fibromyalgia is one of the few chronic pain conditions where supplements have notable trial backing — magnesium malate, CoQ10, vitamin D, and SAMe each have randomized data. If you haven''t had a rheumatology or pain-medicine evaluation, that should come first.

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for…

ENTERIC-COATED tablets — critical for stability and absorption (SAMe degrades in stomach acid)

Stated as 'SAMe tosylate disulfate' or 'SAMe butanedisulfonate' — these are the stable supplement forms

200–400 mg per tablet — allows flexible titration

Third-party tested (ConsumerLab, USP, NSF) — SAMe products have well-documented label-claim accuracy problems

Blister-packed individual tablets (not loose in a bottle) — protects from moisture and oxidation

Stated expiration date — degraded SAMe is inactive even if it looks fine

Be skeptical of…

Non-enteric-coated tablets — degraded by stomach acid; functionally inactive

Loose tablets in an open bottle with no desiccant — SAMe is moisture-sensitive

Mega-dose 1,000+ mg single tablets — split dosing is safer for tolerance

Combos labeled 'mood and joint support' that bundle SAMe with St. John's wort or 5-HTP — serotonin syndrome risk

'Activated SAMe' or 'liposomal SAMe' marketing — no clinical evidence the formulations outperform standard enteric-coated tablets

Frequently asked questions

Is SAMe the same as SAM-e?⌄

Yes. The compound is S-adenosyl-L-methionine, written variously as SAM-e, SAMe, or AdoMet. They all refer to the same molecule.

How does SAMe compare to antidepressants?⌄

Trials show efficacy comparable to tricyclics for depression. It works through different mechanisms (methylation of neurotransmitter pathways) and is sometimes used to augment SSRI response.

Can SAMe help my joints?⌄

Yes, with reasonable evidence. SAMe (600-1,200 mg/day) provides similar pain relief to NSAIDs for osteoarthritis but with fewer GI side effects. Onset is slower (4-8 weeks).

Why must I take it on an empty stomach?⌄

Food slows absorption. SAMe is unstable in stomach acid; the enteric coating delays release until the intestine, where it absorbs better without food competition.

Is SAMe safe long-term?⌄

European clinical experience supports good long-term tolerability. Take with B-vitamins to keep homocysteine in check. Discuss with a clinician if used beyond a few months, especially if taking other medications.

References by claim

Major depressive disorder (mild–moderate)

Limveeraprajak et al., 2024 — Progress in Neuropsychopharmacology & Biological Psychiatry (2024) link

Hardy et al., 2002 (AHRQ) — AHRQ Evidence Report/Technology Assessment No. 64 (2002) link

NCCIH — S-Adenosyl-L-Methionine (SAMe) In Depth — National Center for Complementary and Integrative Health (2024) link

Osteoarthritis (knee, hip) pain

Najm et al., 2004 — BMC Musculoskeletal Disorders (2004) link

Other references

S-Adenosyl methionine on Wikidata — Wikidata link

S-Adenosyl-L-methionine (ChEBI:15414) — ChEBI link

Track SAMe with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store

Evidence-based·Last reviewed May 31, 2026·Evidence current as of May 31, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.